Kronos Bio Announces Changes to Board of Directors
April 11 2023 - 4:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
the appointment of Katherine Vega Stultz to its Board of Directors,
replacing Otello Stampacchia, Ph.D., who stepped down as of March
31, 2023.
“We are very pleased to welcome Katherine to our Board of
Directors. She brings a wealth of both biopharmaceutical leadership
experience and oncology drug development. I also want to thank
Otello for his dedicated service to Kronos. He has provided
valuable insights and guidance during his time on the Board,” said
Norbert Bischofberger, Ph.D., President and Chief Executive Officer
of Kronos Bio. “I am confident the addition of Katherine to our
board will be invaluable as we continue to advance our robust
preclinical and clinical pipeline.”
“I am delighted to join the Kronos Bio Board at this exciting
time, as the company leverages its expertise to develop innovative
therapies for difficult to treat cancers,” said Ms. Stultz. “I look
forward to partnering with this seasoned board and management team
to help guide the company as it advances its research and
development programs”.
Ms. Stultz has over 25 years of experience in the
biopharmaceutical industry and currently serves as the President
and Chief Executive Officer of Ocelot Bio. Prior to this role, Ms.
Stultz served as Chief Operating Officer at Graphite Bio.
Previously, she spent 15 years at Celgene, where she held
leadership roles including General Manager of Portugal and Spain;
Corporate Vice President, Global Project and Portfolio Management
for Hematology/Oncology; and Executive Director, Global Project
Leader and U.S. Brand Leader. She began her career at Eli Lilly
& Company and ConvaTec. Ms. Stultz earned her B.S. in
mechanical engineering from Cornell University.
About Kronos Bio, Inc.Kronos Bio is a
biopharmaceutical company that is advancing two investigational
compounds in clinical trials for patients with cancer. The company
is developing the CDK9 inhibitor KB-0742 as a treatment for
MYC-amplified solid tumors and other transcriptionally addicted
solid tumors and lanraplenib, a next-generation SYK inhibitor, for
patients with FLT3-mutated acute myeloid leukemia. The company’s
scientific focus is on developing medicines that target the
dysregulated transcription that is the hallmark of cancer and other
serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research
facility in Cambridge, Mass. For more information, visit
www.kronosbio.com or follow the company on LinkedIn.
Investors:Claudia StyslingerArgot
Partners212-600-1902kronosbio@argotpartners.com
Media: Leo Vartorella/David RosenArgot
Partners212-600-1902kronosbio@argotpartners.com
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kronos Bio (NASDAQ:KRON)
Historical Stock Chart
From Jul 2023 to Jul 2024